Page last updated: 2024-11-12
13-ethyl-gon-4-ene-3,17-dione
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
13-ethyl-gon-4-ene-3,17-dione: impurity found in Chinese norgestrel; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 10379264 |
| SCHEMBL ID | 1422567 |
| MeSH ID | M0155781 |
Synonyms (42)
| Synonym |
|---|
| 13-ethyl-gon-4-ene-3,17-dione |
| 18a-homo-19-norandrost-4-ene-3,17-dione |
| 18-methyl-19-norandrost-4-ene-3,17-dione |
| gon-4-ene-3,17-dione, 13-ethyl- |
| ec 606-833-1 |
| (+)-13-ethylgon-4-ene-3,17-dione |
| ih07j8f03f , |
| unii-ih07j8f03f |
| 13beta-ethylgon-4-ene-3,17-dione |
| 13beta-ethylgon-4-en-3,17-dione |
| 18-methylestr-4-ene-3,17-dione |
| 13-egedo |
| d-ethyl gonendione |
| 21800-83-9 |
| ethylgonendione |
| E0921 |
| 18-methylestr-4-en-3,17-dione |
| d-ethylgonendione |
| AKOS017343453 |
| SCHEMBL1422567 |
| levonorgestrel impurity l (18-methylester-4-ene-3,17-dione) |
| 13beta-ethyl-gon-4-en-3,17-dione |
| SBLHOJQRZNGHLQ-ATIFRJIPSA-N |
| 13-ethylgon-4-ene-3,17-dione |
| Q-102817 |
| 23477-67-0 |
| 18-methyl-estr-4-ene-3,17-dione |
| 13-ethylgon-4-ene-3,17-dione (levodione; 18-methyl-19-norandrost-4-ene-3,17-dione) |
| dl-ethylgonedione |
| (8r,9s,10r,13s,14s)-13-ethyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,17-dione |
| (8r,9s,10r,13s,14s)-13-ethyl-7,8,9,10,11,12,13,14,15,16-decahydro-1h-cyclopenta[a]phenanthrene-3,17(2h,6h)-dione |
| 13-ethyl-gon-4-en-3,17-dione |
| mfcd08457890 |
| levonorgestrel ep impurity l |
| levodione; d-ethyl gonendione; 13-ethylgon-4-ene-3,17-dione; (+)-13-?-ethylgon-4-ene-3,17-dione; 18-methyl-19-norandrost-4-ene-3,17-dione; 18-methylestr-4-ene-3,17-dione |
| T72090 |
| levonorgestrel impurity [ep impurity] |
| levodione [ep impurity] |
| (+)-13.beta.-ethylgon-4-ene-3,17-dione |
| gon-4-ene-3,17-dione, 13-ethyl-, (+/-)- |
| DTXSID801020560 |
| (3as,3br,9ar,9bs,11as)-11a-ethyl-1h,2h,3h,3ah,3bh,4h,5h,7h,8h,9h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthrene-1,7-dione |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.72
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.72) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||